Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||biliary tract cancer||not applicable||M7824||Phase I||Actionable||In a Phase I trial, Bintrafusp alfa (M7824) treatment in patients with advanced biliary tract cancer resulted in an objective response rate of 20% (6/30), including two complete responses and four partial responses, and led to an additional six patients demonstrating stable disease, and median progression-free survival of 2.5 months, and median overall survival of 12.7 months (PMID: 32461347; NCT02699515).||32461347|